Sana Biotechnology Inc
SANAHealthcare|Biotechnology|USA
$3.85
-0.08 (-2.04%)
Financials
Financial Snapshot
Market Cap
$1.07B
Enterprise Value
$25.8M
Revenue (TTM)
$0.00
Net Income (TTM)
$-242.0M
Cash & Equivalents
—
Net Cash/Share
$-0.57
Free Cash Flow (TTM)
$-133.6M
Operating CF (TTM)
$-132.6M
Debt/Equity
0.63
Cash Runway & Burn Rate
Cash on Hand
$0.00
Quarterly Burn
$33.1M
Monthly Burn
$11.0M
Est. Runway
—
| Metric | Trend | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Investments | $30.6M | $139.0M | $378.3M | $551.0M | $424.0M | $205.2M | $152.5M | $138.4M | $101.1M | |
| Operating Cash Flow | $0.00 | $-85.5M | $-138.0M | $-251.1M | $-290.1M | $-253.6M | $-223.2M | $-143.8M | $-132.6M | |
| Free Cash Flow | $0.00 | $-111.6M | $-161.9M | $-280.9M | $-310.9M | $-273.6M | $-256.6M | $-144.8M | $-133.6M | |
| Capital Expenditure | $0.00 | $-26.1M | $-23.9M | $-29.9M | $-20.9M | $-20.0M | $-33.4M | $-938.0K | $-1.1M | |
| Financing Cash Flow | $0.00 | $223.7M | $435.7M | $631.8M | $4.9M | $31.6M | $199.7M | $128.7M | $127.6M |
R&D Spending
R&D (TTM)
$159.4M
R&D Intensity
—
R&D Growth YoY
-1.2%
| Metric | Trend | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | |
| R&D Expense | $0.00 | $119.4M | $257.9M | $306.5M | $201.0M | $212.8M | $206.8M | $161.4M | $159.4M | |
| R&D % of Revenue | — | — | — | — | — | — | — | — | — | |
| SG&A | $0.00 | $21.8M | $28.3M | $50.4M | $71.6M | $73.3M | $64.0M | $44.3M | $44.3M |
Income Statement
| Metric | Trend | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | |
| Cost of Goods Sold | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | |
| Gross Profit | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | |
| R&D | $0.00 | $119.4M | $257.9M | $306.5M | $201.0M | $212.8M | $206.8M | $161.4M | $159.4M | |
| SG&A | $0.00 | $21.8M | $28.3M | $50.4M | $71.6M | $73.3M | $64.0M | $44.3M | $44.3M | |
| Operating Income | $0.00 | $-141.2M | $-286.1M | $-356.9M | $-272.6M | $-286.1M | $-270.8M | $-205.7M | $-203.7M | |
| Interest Expense | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | |
| Pretax Income | $0.00 | $-138.3M | $-285.3M | $-355.9M | $-269.5M | $-283.3M | $-266.8M | $-244.2M | $-242.0M | |
| Net Income | $0.00 | $-130.8M | $-285.3M | $-355.9M | $-269.5M | $-283.3M | $-266.8M | $-244.2M | $-242.0M | |
| EPS (Diluted) | 0.00 | -1.00 | -1.63 | -2.14 | -1.43 | -1.46 | -1.16 | -0.96 | -0.93 | |
| EBITDA | $0.00 | $-139.3M | $-280.2M | $-345.8M | $-256.9M | $-268.6M | $-255.3M | $-193.0M | $-192.2M | |
| Shares Out. (M) | - | 130.27 | 175.31 | 166.43 | 188.34 | 194.54 | 230.89 | 253.23 | 276.86 |
Balance Sheet
| Metric | Trend | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $30.6M | $80.0M | $124.8M | $253.0M | $176.8M | $133.5M | $127.6M | $71.9M | $83.8M | |
| Marketable Securities | $0.00 | $59.0M | $253.5M | $298.0M | $247.2M | $71.7M | $24.9M | $66.5M | $17.3M | |
| Total Current Assets | $32.6M | $144.3M | $384.5M | $558.1M | $444.4M | $213.5M | $160.8M | $148.7M | $111.7M | |
| Total Assets | $34.3M | $415.2M | $730.3M | $1.13B | $822.7M | $565.3M | $501.0M | $416.9M | $373.6M | |
| Total Current Liabilities | $1.8M | $19.3M | $31.5M | $99.2M | $111.5M | $64.5M | $45.4M | $78.7M | $86.3M | |
| Long-Term Debt | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | |
| Total Liabilities | $47.5M | $557.7M | $1.15B | $400.9M | $323.4M | $277.8M | $250.5M | $256.0M | $254.4M | |
| Stockholders' Equity | $-13.2M | $-142.5M | $-421.2M | $728.5M | $499.3M | $287.5M | $250.5M | $160.9M | $119.2M | |
| Retained Earnings | $-13.2M | $-144.1M | $-429.4M | $-785.4M | $-1.05B | $-1.34B | $-1.60B | $-1.85B | $-1.90B |
Cash Flow Statement
| Metric | Trend | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | $0.00 | $-85.5M | $-138.0M | $-251.1M | $-290.1M | $-253.6M | $-223.2M | $-143.8M | $-132.6M | |
| Capital Expenditure | $0.00 | $-26.1M | $-23.9M | $-29.9M | $-20.9M | $-20.0M | $-33.4M | $-938.0K | $-1.1M | |
| Free Cash Flow | $0.00 | $-111.6M | $-161.9M | $-280.9M | $-310.9M | $-273.6M | $-256.6M | $-144.8M | $-133.6M | |
| Investing Cash Flow | $0.00 | $-87.9M | $-252.6M | $-245.8M | $210.6M | $172.0M | $17.5M | $-40.2M | $-7.4M | |
| Financing Cash Flow | $0.00 | $223.7M | $435.7M | $631.8M | $4.9M | $31.6M | $199.7M | $128.7M | $127.6M | |
| Issuance of Stock | $0.00 | $0.00 | $0.00 | $631.8M | $601.0K | $31.6M | $181.0M | $0.00 | $109.5M | |
| Repurchase of Stock | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | |
| Issuance of Debt | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $27.0M | $188.7M | $126.4M | $0.00 | |
| Payments of Debt | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $-347.0K | $-91.0K | |
| Stock Based Comp. | $0.00 | $1.5M | $5.8M | $22.4M | $38.3M | $35.5M | $37.7M | $25.5M | $24.1M | |
| Net Change in Cash | $0.00 | $50.4M | $45.1M | $134.9M | $-74.6M | $-49.9M | $-6.0M | $-55.3M | $-12.3M |
Dilution Tracker
Shares outstanding grew 66.3% over 5 years — significant dilution
Shares Outstanding
277M
5-Year Share Growth
+66.3%
Stock Issuance (TTM)
$109.5M
| Metric | Trend | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
| Shares Out. (M) | - | 130.27 | 175.31 | 166.43 | 188.34 | 194.54 | 230.89 | 253.23 | 276.86 | |
| YoY Change % | — | — | 34.6% | -5.1% | 13.2% | 3.3% | 18.7% | 9.7% | 9.3% | |
| Stock Issuance | $0.00 | $0.00 | $0.00 | $631.8M | $601.0K | $31.6M | $181.0M | $0.00 | $109.5M | |
| Stock Repurchase | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | |
| Stock Based Comp. | $0.00 | $1.5M | $5.8M | $22.4M | $38.3M | $35.5M | $37.7M | $25.5M | $24.1M |
Margins & Profitability
| Metric | Trend | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin % | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | |
| Operating Margin % | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | - | |
| Net Margin % | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | - | |
| EBITDA Margin % | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | - | |
| FCF Margin % | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | |
| ROE % | 0.0% | 0.0% | 0.0% | -231.6% | -43.9% | -72.0% | -99.2% | -118.7% | -149.9% | |
| ROA % | 0.0% | -58.2% | -49.8% | -38.3% | -27.6% | -40.8% | -50.0% | -53.2% | -59.5% | |
| R&D / Revenue | - | - | - | - | - | - | - | - | - |
Valuation
P/E (TTM)At Loss
HistoricalAt Loss / At Loss / At Loss
Industry Med.27.51
P/S—
Historical— / — / —
Industry Med.9.49
P/B8.70
Historical— / — / 8.70
Industry Med.2.93
EV/EBITDA-5.43
Historical-5.43 / — / —
Industry Med.13.02
EV/Revenue—
Historical— / — / —
Industry Med.8.59
P/FCF—
Historical— / — / —
Industry Med.27.13
Intrinsic Value Models
| Metric | Trend | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
| PE Ratio | N/A | N/A | N/A | At Loss | At Loss | At Loss | At Loss | At Loss | At Loss | |
| PS Ratio | - | - | - | - | - | - | - | - | 0.00 | |
| PB Ratio | 0.00 | 0.00 | 0.00 | 3.93 | 1.51 | 2.81 | 1.46 | 6.75 | 8.70 | |
| EV/EBITDA | 0.00 | 0.00 | 0.00 | -7.01 | -1.71 | -2.63 | -1.20 | -5.32 | -5.43 | |
| EV/Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Analyst Estimates & Quality
Altman Z-Score
—
Distress
Piotroski F-Score
1
Weak
Beneish M-Score
—
Possible Manipulator
Forward Estimates
| Metric | Current Year | Next Year | 2 Years Out |
|---|---|---|---|
| Revenue | $0.00M | $0.00M | $0.00M |
| Net Income | $-177.99M | $-198.59M | $-231.48M |
| EPS | -0.62 | -0.60 | -0.60 |
| Book Value per Share | 0.42 | 0.40 | 0.35 |
| Operating Cash Flow per Share | -0.62 | -0.45 | -0.34 |
| Operating CF | $-171.65M | $-123.20M | $-94.13M |